{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:48:17Z","timestamp":1760384897334,"version":"3.35.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[1990,4,1]],"date-time":"1990-04-01T00:00:00Z","timestamp":638928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chest"],"published-print":{"date-parts":[[1990,4]]},"DOI":"10.1378\/chest.97.4_supplement.168s","type":"journal-article","created":{"date-parts":[[2008,10,11]],"date-time":"2008-10-11T13:23:22Z","timestamp":1223731402000},"page":"168S-171S","source":"Crossref","is-referenced-by-count":12,"special_numbering":"S","title":["A New Short Infusion Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Venous Thromboembolic Disease"],"prefix":"10.1016","volume":"97","author":[{"given":"M.N.","family":"Levine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.G.G.","family":"Turpie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cruickshank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hirsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1378\/chest.97.4_Supplement.168S_bib1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-2007-1003487","article-title":"Optimal dosage regimens of tissue-type plasminogen activator","volume":"13","author":"Agnelli","year":"1987","journal-title":"Semin Thromb Hemost"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1161\/01.CIR.72.1.178","article-title":"A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits","volume":"72","author":"Agnelli","year":"1985","journal-title":"Circulation"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.V66.2.399.399","article-title":"Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits","volume":"66","author":"Agnelli","year":"1985","journal-title":"Blood"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0049-3848(85)90314-7","article-title":"The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: influence of dosage regimens in rabbits","volume":"40","author":"Agnelli","year":"1985","journal-title":"Thromb Res"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1161\/01.CIR.79.1.125","article-title":"Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model","volume":"79","author":"Clozel","year":"1989","journal-title":"Circulation"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib6","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1161\/01.CIR.78.1.214","article-title":"Treatment of canine embolic pulmonary hypertension with recombinant tissue plasminogen activator: efficacy of dosing regimens","volume":"78","author":"Shiffman","year":"1988","journal-title":"Circulation"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib7","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/01.CIR.79.4.929","article-title":"Recombinant tissue-type plasminogen activator in canine embolic pulmonary hypertension: effects of bolus versus short-term administration on dynamics of thrombolysis and on pulmonary vascular pressure-flow characteristics","volume":"79","author":"Prewitt","year":"1989","journal-title":"Circulation"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0049-3848(88)90071-0","article-title":"Bolus dose response characteristics of single chain urokinase plasminogen activator in a dog model of arterial thrombosis","volume":"52","author":"Badylak","year":"1988","journal-title":"Thromb Res"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0049-3848(88)90283-6","article-title":"Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis","volume":"51","author":"S\u00f6hngen","year":"1988","journal-title":"Thromb Res"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib10","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/0002-9149(85)90710-6","article-title":"Intravenous urokinase in acute myocardial infarction","volume":"55","author":"Mathey","year":"1985","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(87)92755-3","article-title":"Bolus streptokinase after myocardial infarction","volume":"2","author":"Hall","year":"1987","journal-title":"Lancet"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib12","first-page":"32","article-title":"High-dose systemic streptokinase and acylated streptokinase-plasminogen complex (BRL 26921) in acute myocardial infarction: alterations of the fibrinolytic system and clearance of fibrinolytic activity","volume":"17","author":"K\u00f6hler","year":"1987","journal-title":"Haemostasis"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-0038-1651057","article-title":"Sustained fibrinolysis after administration of t-PA despite its short half-life in the circulation","volume":"57","author":"Eisenberg","year":"1987","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib14","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood.V64.4.907.907","article-title":"Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma","volume":"64","author":"Kruithof","year":"1984","journal-title":"Blood"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1055\/s-0038-1650023","article-title":"On the regulation and control of fibrinolysis","volume":"43","author":"Collen","year":"1980","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","article-title":"Thrombolysis in Myocardial Infarction (TIMI) trial: Phase 1. Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase","volume":"11","author":"Rao","year":"1988","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1378\/chest.97.4_Supplement.168S_bib17","doi-asserted-by":"crossref","first-page":"88S","DOI":"10.1378\/chest.95.2_Supplement.88S","article-title":"Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism","volume":"95","author":"Fennerty","year":"1989","journal-title":"Chest"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0735-1097(89)90096-X","article-title":"Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleediing complications, but not to coronary patency","volume":"14","author":"Arnold","year":"1989","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib19","unstructured":"Hirsh J, Ginsberg JS, Weitz JI. Advances in antithrombotic therapy. Presented at Haematology 1989-Education Program of the American Society of Hematology, 31st annual meeting; Atlanta, 1989"},{"issue":"suppl II","key":"10.1378\/chest.97.4_Supplement.168S_bib20","first-page":"352","article-title":"Tissue plasminogen activator associated bleeding is increased by the presence of a lysing thrombus","volume":"78","author":"Oczkowski","year":"1988","journal-title":"Circulation"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib21","series-title":"Thrombolysis in cardiovascular disease","first-page":"397","article-title":"Thrombolysis in deep vein thrombosis","author":"Turpie","year":"1989"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/00365517709091499","article-title":"Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate","volume":"37","author":"Teger-Nilsson","year":"1977","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib23","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1172\/JCI103886","article-title":"The maintenance of a sustained thrombolytic state in man: 1. Induction and effects","volume":"38","author":"Fletcher","year":"1959","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib24","series-title":"Computational handbook of statistics","first-page":"18","author":"Bruning","year":"1977"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib25","series-title":"Statistics in medicine","first-page":"151","author":"Colton","year":"1974"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib26","series-title":"Venous thromboembolism","first-page":"198","author":"Hirsh","year":"1981"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib27","unstructured":"Urokinase Pulmonary Embolism Trial. Phase I results. JAMA 1970; 214:2163-72"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib28","doi-asserted-by":"crossref","unstructured":"Urokinase-Streptokinase Embolism Trial. Phase II results. JAMA 1974; 229:1606-13","DOI":"10.1001\/jama.229.12.1606"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0022-3565(25)21520-8","article-title":"Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells","volume":"231","author":"Collen","year":"1984","journal-title":"J Pharm Exp Therapy"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib30","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/301214a0","article-title":"Cloning and expression of human tissue-type plasminogen activator cDNA in E coli","volume":"301","author":"Pennica","year":"1983","journal-title":"Nature"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib31","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1016\/S0021-9258(19)81051-7","article-title":"Kinetics of the activation of plasminogen by human tissue plasminogen activator","volume":"257","author":"Hoylaerts","year":"1982","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-198631010-00001","article-title":"Tissue-type plasminogen activator: therapeutic potential in thrombotic disease states","volume":"31","author":"Collen","year":"1986","journal-title":"Drugs"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib33","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.70.6.1012","article-title":"Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized placebo controlled trial","volume":"70","author":"Collen","year":"1984","journal-title":"Circulation"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib34","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0140-6736(85)92208-1","article-title":"Randomized trial of intravenous recombinant human tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction","volume":"1","author":"Verstraete","year":"1985","journal-title":"Lancet"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib35","doi-asserted-by":"crossref","unstructured":"TIMI Study Group. The Thrombolysis in Myocardial Infarction Trial. N Engl J Med 1985; 312:932-36","DOI":"10.1056\/NEJM198504043121437"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib36","doi-asserted-by":"crossref","unstructured":"Anglo-Scandinavian Study of Thrombolysis (ASSET). Trial of tissue plasminogen activator or mortality reduction in acute myocardial infarction. Lancet 1988; 2:525-30","DOI":"10.1016\/S0140-6736(88)92656-6"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib37","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(86)90411-3","article-title":"Acute pulmonary embolism treated with tissue plasminogen activator","volume":"2","author":"Goldhaber","year":"1986","journal-title":"Lancet"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(88)92354-9","article-title":"Randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism","volume":"2","author":"Goldhaber","year":"1988","journal-title":"Lancet"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1161\/01.CIR.77.2.353","article-title":"Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism","volume":"77","author":"Verstraete","year":"1988","journal-title":"Circulation"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib40","series-title":"Tissue plasminogen activator in thrombolytic therapy","first-page":"131","article-title":"Thrombolytic therapy in venous thromboembolism","author":"Turpie","year":"1987"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib41","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1172\/JCI113001","article-title":"Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator","volume":"79","author":"Owen","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib42","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1161\/01.CIR.72.1.178","article-title":"A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits","volume":"72","author":"Agnelli","year":"1985","journal-title":"Circulation"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib43","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0049-3848(85)90314-7","article-title":"The thrombolytic and hemorrhagic effects of tissue-type plasminogen activator: influence of dosage regimens in rabbits","volume":"40","author":"Agnelli","year":"1985","journal-title":"Thromb Res"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib44","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.V66.2.399.399","article-title":"Sustained thrombolysis with DNA-recombinant tissue-type plasminogen activator in rabbits","volume":"66","author":"Agnelli","year":"1985","journal-title":"Blood"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib45","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000205234","article-title":"Gerinnungs physiologische Schnellmethode zur Bestimmung des Fibrinogens","volume":"17","author":"van Clauss","year":"1957","journal-title":"Acta Haematol (Basel)"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib46","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/00365517709091499","article-title":"Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate","volume":"37","author":"Teger-Nilsson","year":"1977","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib47","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood.V68.6.1280.1280","article-title":"Proteolysis of platelet glycoprotein Ib by plasmin is facilitated by plasmin lysine-binding regions","volume":"68","author":"Adelman","year":"1986","journal-title":"Blood"},{"key":"10.1378\/chest.97.4_Supplement.168S_bib48","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/01.CIR.75.6.1192","article-title":"A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris","volume":"75","author":"Gold","year":"1987","journal-title":"Circulation"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215411572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215411572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T18:08:37Z","timestamp":1738433317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215411572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,4]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1990,4]]}},"alternative-id":["S0012369215411572"],"URL":"https:\/\/doi.org\/10.1378\/chest.97.4_supplement.168s","relation":{},"ISSN":["0012-3692"],"issn-type":[{"type":"print","value":"0012-3692"}],"subject":[],"published":{"date-parts":[[1990,4]]}}}